Akari Therapeutics, formally known as Celsus Therapeutics, officially announced a $75 million private placement.
The company, a development-stage biopharmaceutical company, shared the finalized news about the financing that came from investors led by Deerfield, and including Venrock, Vivo Capital, Foresite Capital, New Enterprise Associates, QVT Financial, RA Capital Management and certain other institutional investors.
The proceeds will be dedicated to the company’s C5 complement inhibitor, Coversin, through Phase 2 clinical trials in paroxysmal nocturnal hemoglobinuria (PNH), Guillain Barr syndrome (GBS) atypical, and Hemolytic Uremic Syndrome (aHUS).
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
“We are excited to advance the development of Coversin into several clinical indications,” said Gur Roshwalb, Chief Executive Officer of Akari Therapeutics, according to MarketWatch. “We believe that Coversin has potential to be the next and best-in-class C5 complement therapeutic and this financing provides us with the resources to advance our corporate and clinical goals.”
Dr. Ray Prudo, Executive Chairman stated, “I am delighted to be working with our strong management team to increase shareholder value and I believe Akari has the strategy, vision and support to become a leading player in our sector.”
Photo: Flickr user Images Money
